BCN-PEG3-Val-Cit
Code | Size | Price |
---|
TAR-T17531-100mg | 100mg | Enquire | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T17531-500mg | 500mg | Enquire | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20°C
Images
Documents
Further Information
Bioactivity:
BCN-PEG3-Val-Cit is a PEG-based linker commonly employed in PROTAC synthesis[1]. Additionally, it serves as a cleavable 3 unit PEG linker in the production of antibody-drug conjugates (ADCs)[2].
CAS:
T17531
Molecular Weight:
653.76
Purity:
0.98
SMILES:
O=C(NCCOCCOCCOCCC(N[C@@H](C(C)C)C(N[C@@H](CCCNC(N)=O)C(O)=O)=O)=O)OCC1C2CCC#CCCC21
References
Beck A, et al. Strategies and challenges for the next generation of antibody-drug conjugates. Nat Rev Drug Discov. 2017 May;16(5):315-337.
An S, et al. Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs. EBioMedicine. 2018 Oct;36:553-562.